SEARCH

SEARCH BY CITATION

References

  • 1
    Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010; 51: 206976.
  • 2
    Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 8219.
  • 3
    Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012; 32(Suppl. 1): 88102.
  • 4
    Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195206.
  • 5
    Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 240516.
  • 6
    Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 120717.
  • 7
    Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 241728.
  • 8
    Bruno S, Vierling J, Esteban R, et al. Boceprevir in addition to standard of care enhanced SVR in hepatitis C virus genotype-1 with advanced fibrosis/cirrhosis: subgroup analysis of SPRINT-2 and RESPOND-2 studies. J Hepatol 2011; 54: S4 (abstract).
  • 9
    Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 101424.
  • 10
    Pol S, Roberts SK, Andreone P, et al. Efficacy and safety of telaprevir-based regimen in cirrhotic patients with HCV genotype-1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE phase III study. Hepatology 2011; 54(suppl): 374A (abstract).
  • 11
    Hadacek B, Danton A, Barbé N, et al. Telaprevir French cohort authorization for temporary use in genotype 1 hepatitis C cirrhotic patients with prior partial response or relapse (Abstract). J Hepatol 2012; 56(Suppl. 2): S440.
  • 12
    Hezode C, Dorival C, Zoulim F, et al. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin in cirrhotic non responders. First results of the French early access program (ANRS CO20-CUPIC). J Hepatol 2012; 56(Suppl. 2): S4.
  • 13
    Poordad FF, Lawitz EJ, Reddy KR, et al. A randomized trial comparing ribavirin dose reduction versus erythropoietin for anaemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirin (Abstract). J Hepatol 2012; 56(Suppl. 2): S559.
  • 14
    Kwo P, Ghabril M, Lacerda MA, et al. Use of telaprevir plus peginterferon/ribavirin for null responders post OLT with advanced fibrosis/cholestatic hepatitis C (Abstract).J Hepatol 2012; 56(Suppl. 2): S86.
  • 15
    Coilly A, Roche B, Botta-Fridlund D, et al. Efficacy and safety of protease inhibitors for severe hepatitis C recurrence after liver transplantation: a first multicentric experience (Abstract)J Hepatol 2012; 56(Suppl. 2): S21.
  • 16
    Bourliere M, Khaloun A, Wartelle-Bladou C, et al. Chronic hepatitis C: treatments of the future. Clin Res Hepatol Gastroenterol 2011; 35(Suppl. 2): S8495.
  • 17
    Fusco DN, Chung RT. New protease inhibitors for HCV–help is on the way. J Hepatol 2011; 54: 10879.
  • 18
    Wartelle-Bladou C, Le Folgoc G, Bourliere M, Lecomte L. Hepatitis C therapy in non-genotype 1 patients: the near future. J Viral Hepat 2012; 19: 52536.
  • 19
    Dieterich D, Asselah T, Guyader D, et al. SILEN-C3: treatment for 12 or 24 weeks with BI201335 combinated with peginterferon alfa-2a and ribavirin in treatment naive patients with chronic genotype 1 HCV infection (Abstract). Hepatology 2011; 54(suppl): 378A.
  • 20
    Zeuzem S, Berg T, Gane E, et al. TMC435 in HCV genotype 1 patients who have failed previous pegylated interferon ribavirin treatment: Final SVR24 results of the ASPIRE trial (Abstract).J Hepatol 2012; 56(Suppl. 2): S1.
  • 21
    Pockros P, Jensen D, Tsai N, et al. SVR12 among G1/4 treatement naive patients receiving mericitabine in combination with PEG-IFN alfa-2a/ribavirin; Interim analysis from the JUMP-C study (Abstract). J Hepatol 2012; 56(suppl .2): S477.
  • 22
    Wedemeyer H, Jensen D, Herring R Jr, et al. Efficacy and safety of mericitabine in combination with PEG-IFN alfa-2a/ribavirin in genotype1/4 treatment naive HCV patients. Final analysis from the PROPEL study (Abstract).J Hepatol 2012; 56(Suppl. 2): S481.
  • 23
    Kowdley KV, Lawitz E, Crespo I, et al. ATOMIC: 97% RVR for PSI-7977 +  PEG/RBV x 12 week regimen in HCV GT1: an end to response-guided therapy? (Abstract). J Hepatol 2012; 56(Suppl. 2): S1.
  • 24
    Hassanein T, Nelson DR, Lawitz E, et al. PSI-7977 with PEG/RBV elicits rapid declines in HCV RNA in patients with HCV GT-4 and GT-6. Global Antiviral J 2011; 7(Suppl. 1 HEP DART 2011): 57 (abstract).
  • 25
    Gane EJ, Stedman C, Hyland RH, et al. Once daily PSI-7977 plus RBV: pegylated interferon alfa not required for complete rapid viral response in treatment naive patients with HCV GT2 or GT3 (Abstract)Hepatology 2011; 54: 377A.
  • 26
    Lawitz E, Rodriguez-Torres M, Cornpropst MT, Denning JMC. D., McNair L, Fang L, et al. The effect of hepatic impairment on the pharmacokinetics and antiviral activity of PSI-7977in hepatitis C infected subjects treated for seven days (Abstract). J Hepatol 2012; 56(Suppl. 2): S4456.
  • 27
    Pol S, Ghalib RH, Rustgi VK, et al. First report of SVR 12 for NS5A replication complex inhibitor BMS-790052 in combination with PEG-IFN and RBV: phase 2A trial in treatment naive HCV-genotype 1 subjects (Abstract). J Hepatol 2011; 54: S5445.
  • 28
    Suzuki F, Ikeda K, Toyota J, et al. Dual oral therapy with the NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1B infected null responders or ineligible/intolerant to peginterferon/ribavirin (Abstract). J Hepatol 2012; 56(Suppl. 2): S78.
  • 29
    Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 21624.
  • 30
    Ratziu V, Gadano A, Pol S, et al. Triple therapy with daclatasvir, peginterferon alfa-2a and ribavirin in HCV infected prior null and partial responders: 12 weeks results of phase s COMMAND-2 trial (Abstract). J Hepatol 2012; 56(Suppl. 2): S4789.
  • 31
    Alberti A, Chuang WL, Flisiak R, et al. Alisporivir plus peginterferon/ribavirin in HCV genotype 1 treatment-experienced patients achieves primary endpoint with superior efficacy at treatment week 12 compared to retreatment with PR (Abstract). J Hepatol 2012; 56(Suppl. 2): S553.
  • 32
    Zeuzem S, Soriano V, Asselah T, et al. SVR4 and SVR12 with an interferon-free regimen of BI201335 and BI207127 + /- ribavirin in treatment naive patients with chronic genotype 1 HCV infection; interim results of SOUND-C2 (Abstract).J Hepatol 2012; 56(Suppl. 2): S45.
  • 33
    Soriano V, Gane E, Angus P, et al. The efficacy and safety of the interferon-free combination of BI201335 and BI207127 in genotype 1 HCV patients with cirrhosis. Interim analysis from SOUND-C2 (Abstract).J Hepatol 2012; 56(Suppl. 2): S559.